NCT00852137

A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis

A Randomized, Double-blind, Vehicle-controlled Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Peplin · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This Phase II study is designed to evaluate the pharmacokinetics of PEP005 (ingenol mebutate) Gel, 0.05% when applied in a maximal use setting to the dorsal aspect of the forearm in patients with actinic keratoses

Conditions

• Actinic Keratosis

Interventions

Type	Name	Description
DRUG	PEP005 (ingenol mebutate) Gel, 0.05%	PEP005 (ingenol mebutate) Gel 0.05% once daily for 2 consecutive days
DRUG	Vehicle Gel	Vehicle Gel once daily for 2 consecutive days

Timeline

• Start date: 2009-03-01
• Primary completion: 2009-06-01
• Completion: 2009-06-01
• First posted: 2009-02-26
• Last updated: 2015-03-06
• Results posted: 2012-05-28

Locations

1 site across 1 country: United States